Haemonetics (NYSE:HAE) said yesterday that it plans to take a pre-tax charge of $26 million, including $17 million worth of “termination benefits,” as part of another round of layoffs aimed at boosting profitability and growth.
The Braintree, Mass.-based blood management company also said it named Chris Simon to be its new CEO, replacing interim chief Ron Gelbman, who took the reins after the September 2015 departure of Brian Concannon.
Haemonetics also issued its sales and earnings guidance for the fiscal 2017 year ending next April that missed the consensus expectation on Wall Street.
The Braintree, Mass.-based blood management company also said it named Chris Simon to be its new CEO, replacing interim chief Ron Gelbman, who took the reins after the September 2015 departure of Brian Concannon.
Haemonetics also issued its sales and earnings guidance for the fiscal 2017 year ending next April that missed the consensus expectation on Wall Street.
